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OBJECTIVES The goal of this study was to determine the influence of gender on baseline characteristics,
response to treatment, and prognosis in patients with heart failure (HF) and impaired left
ventricular ejection fraction (LVEF).
BACKGROUND Under-representation of women in HF clinical trials has limited our understanding of
gender-related differences in patients with HF.
METHODS The impact of gender was assessed in the Beta-Blocker Evaluation of Survival Trial (BEST)
which randomized 2,708 patients with New York Heart Association class III/IV and LVEF
0.35 to bucindolol versus placebo. Women (n  593) were compared with men (n 
2,115). Mean follow-up period was two years.
RESULTS Significant differences in baseline clinical and laboratory characteristics were found. Women
were younger, more likely to be black, had a higher prevalence of nonischemic etiology, higher
right and left ventricular ejection fraction, higher heart rate, greater cardiothoracic ratio,
higher prevalence of left bundle branch block, lower prevalence of atrial fibrillation, and lower
plasma norepinephrine level. Ischemic etiology and measures of severity of HF were found to
be predictors of prognosis in women and men. However, differences in the predictive values
of various variables were noted; most notably, coronary artery disease and LVEF appear to be
stronger predictors of prognosis in women. In the nonischemic patients, women had a
significantly better survival rate compared with men.
CONCLUSIONS In HF patients with impaired LVEF, significant gender differences are present, and the
prognostic predictive values of some variables vary in magnitude between women and men.
The survival advantage of women is confined to patients with nonischemic etiology. (J Am
Coll Cardiol 2003;42:2128–34) © 2003 by the American College of Cardiology Foundation
The differential impact of gender on the occurrence, pre-
sentation, prognosis, and response to treatment in cardio-
vascular diseases has received considerable attention in the
past decade (1–3). Under-representation of women, how-
ever, has been a consistent finding in clinical trials (4,5),
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including heart failure (HF) (6–8) trials, which has resulted
in several challenges to clinicians and investigators including
lack of appreciation of the differences in clinical character-
istics between men and women, and limitation on the ability
to analyze various clinical and laboratory variables that could
serve as markers and, potentially, determinants of survival in
women with HF.
The Beta-Blocker Evaluation of Survival Trial (BEST),
following National Heart, Lung, and Blood Institute guide-
lines (9), placed special emphasis on recruitment of women,
and randomization was stratified by etiology, left ventricular
ejection fraction (LVEF), ethnicity, and gender. The large
number of women enrolled in BEST, the extensive charac-
terization of many important baseline clinical and laboratory
characteristics, and randomization by gender provide an
opportunity to delineate gender differences in HF. This
report details the BEST experience in women with HF.
METHODS
The study design was reported (10). All patients had New
York Heart Association (NYHA) class III or IV HF with
an LVEF 0.35, and gave written informed consent. The
protocol was approved by each participating site’s institu-
tional review board.
Randomization to the beta-blocker bucindolol or placebo
was stratified at each clinical site by etiology of HF
(presence or absence of coronary artery disease [CAD]),
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LVEF (0.20 vs. 0.20), gender, and ethnicity (black vs.
non-black).
The trial was conducted at 30 Veterans Administration
Hospital (VA) sites, and 60 non-VA sites. A total of 24,933
patients were screened, including 20,343 males and 4,590
females. Of those, 2,708 (11%) were randomized, including
2,115 (10%) males and 593 (13%) females. Enrollment of
women was 22% overall and 32% at non-VA sites. Etiology
was defined as ischemic by the primary investigator in each
center in the presence of documented CAD or prior
myocardial infarction.
The primary end point of BEST was all-cause mortality.
Secondary end points included cardiovascular mortality,
all-cause and HF hospitalization, the combination of death
and heart transplantation, and LVEF at 3 and 12 months.
Statistical analysis. Gender and treatment group compar-
isons were conducted. For continuous variables, the t test
was used except when the data were non-normal. This was
the case with plasma norepinephrine (PNE), and Wilcoxon
rank-sum test was used. For categorical variables, the
chi-square test was used. The log-rank test was used to
compare survival distributions (mortality rates) by gender
and treatment group. Kaplan-Meier methods were used to
construct survival curves. Cox regression models were used
to examine the effect of covariates of interest on overall
survival and in gender subgroups, and to estimate hazard
ratios and 95% confidence intervals. Univariate analysis of
associations with mortality were conducted within gender
for each hypothesized predictor, followed by multivariate
analyses within gender, with reduction of variables by
backwards elimination of those found not significant at the
p  0.05 level (all models were adjusted for randomized
treatment group assignment). Cox regression analysis was
also used to examine potential interactions between gender,
presence of CAD, and treatment group. The p values are
reported from the paired t test comparing treatment re-
sponse from baseline, at 3 and 12 months, and overall mean
estimates, respectively.
A type I error of 0.05 was used to denote statistical
significance, and p values reported are unadjusted.
RESULTS
Baseline characteristics. Baseline characteristics are pre-
sented in Table 1. Women were younger than men, were
more likely to be black, had a higher prevalence of nonisch-
emic etiology, higher left and right ventricular ejection
fraction (RVEF), higher heart rate, greater cardiothoracic
ratio (CTR), higher blood urea nitrogen/creatinine ratio,
higher prevalence of left bundle branch block (LBBB),
lower prevalence of atrial fibrillation (Afib), current and past
smoking, lesser use of anticoagulants and aspirin, and lower
PNE compared with men.
Response to treatment. In women receiving bucindolol, a
clinically significant slowing of the heart rate was noted at
three months from 83 (beats/min) to 75 (beats/min) that
was sustained at 12 months (p  0.05). The slowing of the
heart rate was significantly greater with bucindolol com-
pared with placebo (p  0.0001). Both RVEF and LVEF
improved at three and 12 months in the study participants.
In the bucindolol group, LVEF increased from 25  7% at
baseline, to 33  13% at 12 months (p  0.05), which was
significantly higher than LVEF in the placebo group mea-
sured at 12 months, 28  12% (p  0.0004). Right
ventricular ejection fraction was measured at 38  14% at
baseline, 42  15% at 12 months in the placebo group (p 
0.05). In the bucindolol group, the corresponding figures
were 37  14% and 47  13% (p  0.05), respectively.
Right ventricular ejection fraction was significantly higher at
12 months in the bucindolol group (p  0.0006).
Survival. No improvement in survival was noted in the
bucindolol group compared with placebo (mortality 26% vs.
29%, respectively, p  0.44). This finding was consistent in
all subgroups regardless of etiology, ethnicity, or the pres-
ence of diabetes.
Analyzing crude mortality by gender demonstrated lower
mortality in women compared with men (27% vs. 33%,
respectively, p  0.02) due to the significant difference in
the nonischemic compared with ischemic group (19% vs.
27%, respectively, p  0.009) (Table 2). New York Heart
Association class III women had lower overall mortality
than men (25% vs. 32%, respectively, p  0.004), and a
lower mortality in nondiabetic women compared with
nondiabetic men (25% vs. 31%, respectively, p  0.03) was
noted as illustrated in Figure 1, which also displays the
hazard ratios by gender for the prespecified variables.
Variables related to prognosis. The following preselected
clinical characteristics and laboratory values were related to
prognosis in a Cox proportional hazards regression model:
NYHA functional class (class IV vs. III), CAD (presence vs.
absence of CAD), ethnicity (black vs. non-black), age, body
mass index (BMI), diabetes history, systolic blood pressure,
LVEF, CTR, QRS duration, Afib (presence vs. absence),
blood urea nitrogen/creatinine ratio, and treatment. Regression
analyses were conducted separately for women and men.
In women, all the above-mentioned variables were found
to be univariate predictors of survival with the exception of
Abbreviations and Acronyms
Afib  atrial fibrillation
BEST  Beta-Blocker Evaluation of Survival Trial
BMI  body mass index
CAD  coronary artery disease
CTR  cardiothoracic ratio
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LVEF  left ventricular ejection fraction
NYHA New York Heart Association
PNE  plasma norepinephrine
RVEF  right ventricular ejection fraction
VA  Veteran’s Administration
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ethnicity, QRS duration, and treatment (Table 3). A par-
allel analysis was carried out in men (Table 4) with similar
results. QRS duration, but not Afib, was found to be a
univariate predictor of survival in men.
Ischemic etiology and measures of the severity of HF
were found to be predictors of survival in multivariate
regression models in both women and men (Tables 5 and 6).
These include CAD, LVEF, systolic blood pressure, CTR,
and blood urea nitrogen/creatinine ratio. Coronary artery
disease and LVEF appeared to be stronger predictors of
prognosis in women (Table 5). Atrial fibrillation and
NYHA were predictors in women, but not in men. QRS
duration, BMI, age, heart rate, diabetes history, and treat-
ment (bucindolol vs. placebo) were found to be predictors of
survival in men only (Table 6).
A multivariate model (Table 7) comparing survival of
females to males and adjusting for major risk factors
indicates that gender is a significant predictor of outcome
(p  0.0046). There was a significant CAD by gender
interaction (p  0.011). The effect of gender on survival
is modified by etiology (ischemic vs. nonischemic). In the
nonischemic group, women have a better survival than
men (p  0.0093); however, in the ischemic group, there
was a trend for a better survival in men (p  0.1516)
(Fig. 2).
Table 1. Baseline Clinical Characteristics by Gender
Characteristics
Women
(n  593)
Men
(n  2,115) p Value
Age (yrs) mean (range) 58  13.3 (19–93) 61  12.0 (21–90)  0.001
Ethnicity
White, non-Hispanic 367 (62%) 1,529 (72%) 0.001
Black, non-Hispanic 180 (30%) 447 (21%)
Other 46 (8%) 139 (7%)
NYHA functional class
III 549 (93%) 1,933 (91%) 0.356
IV 44 (7%) 182 (9%)
Etiology
Ischemic 228 (38%) 1,359 (64%)  0.001
Nonischemic 365 (62%) 756 (36%)
Diabetes mellitus 214 (36%) 750 (35%) 0.778
Hypertension 340 (57%) 1,256 (59%) 0.370
Physical exam
HR (beats/min) 84  12.8 81  13.3  0.001
BMI (kg/m2) 28  6.8 28  5.8 0.318
SBP (mm Hg) 117  18.1 117  18.0 0.883
Baseline medications
ACE inhibitor 536 (90%) 1,934 (91%) 0.423
Digitalis 550 (93%) 1,951 (92%) 0.684
Anticoagulant 246 (41%) 969 (46%) 0.061
Aspirin 214 (36%) 1,001 (47%)  0.001
Afib 29 (5%) 274 (13%)  0.001
LBBB 202 (34%) 478 (23%)  0.001
LVEF (%) 25  7.1 23  7.3  0.001
RVEF (%) 38  13.8 34  13.3  0.001
CTR 59  7.6 55  6.8  0.001
BUN/creatinine 21  9.3 19  7.8  0.001
Sodium (mEq/l) 139  3.2 139  3.4 0.862
PNE (pg/ml) median 398 442 0.007
Current smoker 68 (11%) 406 (19%)  0.001
History of smoking 314 (53%) 1,638 (77%) 0.001
Mean  1 SD.
ACE  angiotensin-converting enzyme; Afib  atrial fibrillation; BMI  body mass index; BUN  blood urea nitrogen;
CTR  cardiothoracic ratio; HR  heart rate; LBBB  left bundle branch block; LVEF  left ventricular ejection fraction;
NYHA  New York Heart Association; PNE  plasma norepinephrine; RVEF  right ventricular ejection fraction; SBP 
systolic blood pressure.
Table 2. Crude Mortality by Gender
Women
(n  593)
Men
(n  2,115)
Log Rank
p Value
Death 163 (27%) 697 (33%) 0.02
CAD 92/228 (40%) 494/1,359 (36%) 0.15
Non-CAD 71/365 (19%) 203/756 (27%) 0.009
LVEF
20 67/178 (38%) 342/847 (40%) 0.62
20 96/415 (23%) 355/1,268 (28%) 0.07
NYHA class
III 136/549 (25%) 613/1,933 (32%) 0.004
IV 27/44 (61%) 84/182 (46%) 0.15
Ethnicity
Black 52/180 (29%) 156/447 (35%) 0.11
Non-black 111/413 (27%) 541/1,668 (32%) 0.05
Diabetes 68/214 (32%) 279/750 (37%) 0.39
No diabetes 95/379 (25%) 418/1,365 (31%) 0.03
CAD coronary artery disease; LVEF left ventricular ejection fraction; NYHA
New York Heart Association.
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DISCUSSION
The large number of women enrolled in BEST coupled
with the detailed assessment of their baseline characteristics
and follow-up data provide an opportunity to address major
issues related to women with HF.
Baseline characteristics and prognostic variables. Several
baseline clinical and laboratory features were found to differ
significantly between women and men. Some characteristics
are expected to confer better prognosis, namely having a
higher prevalence of nonischemic etiology, higher LVEF
(11), lower occurrence of Afib (12), and lower PNE (11).
Some other features, however, have been related to worse
outcome including higher heart rate (13), CTR (11), and
higher prevalence of LBBB (14).
A review of prior studies addressing gender differences in
patients with advanced HF reveals certain common features
in women consistent with our findings including a lower
percentage of ischemic etiology (15–18) a higher percentage
of African Americans (15,16), a higher heart rate (16,18),
LVEF (15,18), CTR (19), higher prevalence of LBBB
(17,19), and lower prevalence of Afib (15,18).
A more favorable outcome among women may theoret-
Figure 1. Hazard ratios for mortality comparing genders for prespecified patient subgroups adjusted for treatment group. CAD  coronary artery disease;
LVEF  left ventricular ejection fraction; NYHA  New York Heart Association.
Table 3. Univariate Predictors of Mortality in Women
Covariate
Hazard
Ratio 95% CI p Value
CAD (CAD vs. no CAD) 2.45 (1.80–3.34) 0.0001
NYHA (class IV vs. class III) 3.27 (2.16–4.95) 0.0001
LVEF (per 1%) 0.95 (0.93–0.97) 0.0001
BUN/creatinine (per 1 U) 1.03 (1.01–1.04) 0.0001
CTR (per 1 U) 1.05 (1.03–1.08) 0.0001
Age (per 1 year) 1.02 (1.01–1.04) 0.0003
SBP (per 1 mm Hg) 0.99 (0.98–0.994) 0.0016
Afib (presence vs. absence) 2.20 (1.29–3.74) 0.0037
BMI (per 1 kg/m2) 0.97 (0.95–0.995) 0.0178
Diabetes (Hx vs. no Hx) 1.45 (1.06–1.97) 0.0209
HR (beats/min) 0.99 (0.98–0.999) 0.0383
QRS duration (per 1 ms) 1.00 (0.999–1.01) 0.1642
Treatment (bucindolol vs. placebo) 0.89 (0.65–1.21) 0.4423
Ethnicity (black vs. non-black) 1.08 (0.78–1.50) 0.6447
For continuous variables, the hazard ratio represents the risk of dying per 1 U increase
in the covariate. Women: 593 total participants, 163 deaths.
CI  confidence interval; Hx  history of. Other abbreviations as in Tables 1 and 2.
Table 4. Univariate Predictors of Mortality in Men
Covariate
Hazard
Ratio 95% CI p Value
CAD (CAD vs. no CAD) 1.47 (1.25–1.73) 0.0001
NYHA (class IV vs. class III) 1.80 (1.43–2.26) 0.0001
LVEF (per 1%) 0.97 (0.96–0.98) 0.0001
BUN/creatinine (per 1 U) 1.04 (1.03–1.05) 0.0001
SBP (per 1 mm Hg) 0.986 (0.98–0.99) 0.0001
CTR (per 1 U) 1.05 (1.03–1.06) 0.0001
QRS duration (per 1 ms) 1.006 (1.00–1.01) 0.0001
Age (per 1 year) 1.02 (1.01–1.03) 0.0001
BMI (per 1 kg/m2) 0.96 (0.95–0.97) 0.0001
Diabetes (Hx vs. no Hx) 1.27 (1.09–1.48) 0.0019
HR (beats/min) 1.006 (1.00–1.01) 0.0430
Treatment (bucindolol vs. placebo) 0.89 (0.77–1.04) 0.1366
Ethnicity (black vs. non-black) 1.14 (0.95–1.36) 0.1516
Afib (presence vs. absence) 1.13 (0.91–1.40) 0.2636
For continuous variables, the hazard ratio represents the risk of dying per 1 U increase
in the covariate. Men: 2,115 total participants, 697 deaths.
Abbreviations as in Tables 1, 2, and 3.
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ically be explained on the basis of the effects of sex
hormones. Women with late menopause were found to have
larger end-systolic volumes, lower LVEF, and lower filling
rates as compared with early menopausal women (20).
Similarly, premenopausal women have lower blood pressure
compared with men of similar age, a pattern that is no
longer seen after menopause (21). Estrogen decreases en-
dothelin levels in postmenopausal women (22), and estro-
gen replacement in perimenopausal women results in reduc-
tion of systolic and diastolic blood pressure, and in total
body norepinephrine spillover in response to mental stress
(23). The potential vasodilator effect of estrogen may be
mediated through the renin-angiotensin system, bradykinin,
or nitric oxide (24–26). Moreover, sex hormones exhibit a
favorable effect on hemostasis and thrombolysis. Signifi-
cantly lower levels of plasminogen activator inhibitor were
found in premenopausal women as compared with post-
menopausal women or to men of similar age (27).
Gender-related differences in geometric remodeling and
earlier onset of impaired LV systolic function in males was
noted in animal models (28) as well as in humans with aortic
stenosis (29) and hypertension (30). Myocyte cell loss
pattern favoring females (31) and gender differences in gene
expression have also been reported (32), and, very recently,
reduced hypertrophy in women in postinfarction remodel-
ing was speculated to reflect fundamental differences in
cellular remodeling (33).
However, a more likely explanation is that these variables
were derived from studies that have enrolled predominantly
men. Our data indicate a differential prognostic value for
some characteristics. For example, Afib was found to be a
predictor in women but not in men. On the other hand,
QRS duration and BMI were predictors only in men.
Because of the relatively limited sample size, one should be
cautious not to over-interpret these differences. However,
two interesting findings should be mentioned. For every 1%
increase in LVEF, there was a corresponding 4% decrease in
mortality in women compared with a 1% decrease in men.
Similarly, CAD conferred a 2.5-fold increase in the risk of
mortality in women compared with a 1.5-fold increase in
men. Thus, LVEF and CAD appear to be stronger predic-
tors of prognosis in women.
Comparison with previous survival studies. A study in a
young population of 65 women and 238 men with idio-
pathic dilated cardiomyopathy who were enrolled consecu-
tively found no difference in survival rates between men and
women (19). Adams et al. (15) reported their experience
with 177 women and 380 men with HF and impaired left
ventricular systolic function consecutively enrolled in an
outpatient HF clinic. They found a significantly better
survival rate for women with nonischemic etiology. Similar
findings were reported from the Flolan International Ran-
domized Survival trial, in 112 women and 359 men (16).
Recently, Simon et al. (17) reported the survival rates in 515
female and 2,132 men in the Cardiac Insufficiency Bisopro-
lol study. Although they confirmed better survival for
women compared with men, this difference was predomi-
nantly noted in the undefined etiology, and no difference in
survival was seen between women and men in the nonisch-
emic group. Likewise, in Metoprolol CR/XL Randomized
Intervention Trial In Heart Failure, women had a 37%
lower risk of dying than men after adjusting for baseline
differences including ischemic etiology (18). Findings from
Table 7. Multivariate Predictors of Mortality in Women and Men
Covariate
Hazard
Ratio 95% CI
Adjusted
p Value
Creatinine (per 1 mg/dl) 2.18 (1.87–2.55)  0.0001
NYHA (class IV vs. class III) 1.51 (1.23–1.85)  0.0001
SBP (per 1 mm Hg) 0.99 (0.985–0.993)  0.0001
LVEF (per 1%) 0.97 (0.96–0.98)  0.0001
CAD (CAD vs. no CAD) 1.91 (1.40–2.63)  0.0001
Age (per 1 year) 1.01 (1.005–1.02) 0.0005
Diabetes (Hx vs. no Hx) 1.25 (1.08–1.44) 0.0026
Body mass index (per 1 kg/m2) 0.98 (0.97–0.99) 0.0029
Gender (male vs. female) 1.09 (0.83–1.43) 0.0046
Treatment (bucindolol vs. placebo) 0.81 (0.69–0.94) 0.0233
Ethnicity (black vs. non-black) 0.93 (0.74–1.18) 0.1818
CAD-by-gender interaction 0.0107
Ethnicity-by-treatment interaction 0.0980
For continuous variables, the hazard ratio represents the risk of dying per 1 U increase
in the covariate. Final model based on 2,705 participants, 859 deaths.
Abbreviations as in Tables 1, 2, and 3.
Table 5. Multivariate Predictors of Mortality in Women
Covariate
Hazard
Ratio 95% CI p Value
CAD (CAD vs. no CAD) 2.47 (1.80–3.41) 0.0001
NYHA (class IV vs. class III) 2.63 (1.72–4.04) 0.0001
BUN/creatinine (per 1 U) 1.02 (1.01–1.04) 0.0025
CTR (per 1 U) 1.04 (1.01–1.06) 0.0027
LVEF (per 1%) 0.96 (0.94–0.99) 0.0043
Afib (presence vs. absence) 2.07 (1.16–3.69) 0.0137
SBP (per 1 mm Hg) 0.99 (0.98–0.999) 0.0294
Treatment (bucindolol vs. placebo) 0.82 (0.60–1.13) 0.2216
For continuous variables, the hazard ratio represents the risk of dying per 1 U increase
in the covariate. Women: 593 total participants, 163 deaths. Final model based on 580
participants, 158 deaths.
Abbreviations as in Tables 1 and 2.
Table 6. Multivariate Predictors of Mortality in Men
Covariate
Hazard
Ratio 95% CI p Value
BUN/creatinine (per 1 U) 1.02 (1.015–1.03) 0.0001
CTR (per 1 U) 1.03 (1.02–1.05) 0.0001
Age (per 1 year) 1.02 (1.01–1.023) 0.0004
CAD (CAD vs. no CAD) 1.33 (1.12–1.59) 0.0015
BMI (per 1 kg/m2) 0.98 (0.96–0.99) 0.0026
SBP (per 1 mm Hg) 0.99 (0.988–1.00) 0.0033
HR (beats/min) 1.01 (1.00–1.02) 0.0054
Diabetes (Hx vs. no Hx) 1.25 (1.06–1.47) 0.0081
LVEF (per 1%) 0.99 (0.98–1.00) 0.0225
QRS duration (per 1 ms) 1.002 (1.00–1.01) 0.0381
Treatment (bucindolol vs. placebo) 0.85 (0.73–0.99) 0.0386
For continuous variables, the hazard ratio represents the risk of dying per 1 U increase
in the covariate. Final model based on 2,035 participants, 676 deaths.
Abbreviations as in Tables 1, 2, and 3.
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BEST, however, indicate that the survival advantage of
women was confined to the nonischemic patients. There-
fore, one has to conclude that the survival advantage of
women cannot be explained entirely on the basis of higher
prevalence of nonischemic etiology. It is likely that other
confounders not identified by measured baseline clinical and
laboratory characteristics play a role.
Study limitations. Despite the attempt to maximize en-
rollment of women and to collect all pertinent information
relevant to gender differences, this effort is by no means
complete. The sample size is limited, and there are several
factors that have not been measured. For example, gender-
related differences in pharmacokinetics have been identified
for a number of drugs including beta-blockers (34), and
socioeconomic status has not been addressed. We consider
our findings exploratory in nature and hypothesis-generating.
Conclusions. Major baseline differences in clinical and
laboratory characteristics exist between men and women.
The prognostic role of various predictors may vary in
magnitude between genders, and the survival advantage of
women in our study was confined to the nonischemic
etiology. These data indicate that information collected on
men with HF cannot be assumed to apply similarly or with
the same magnitude to women, emphasize the importance
of accounting for these differences in designing clinical
trials, and highlight the need for both stratifying entry by
gender and enrolling more women in HF trials.
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